Shanghai Junshi Biosciences CO Ltd (OP: SHJBF )

1.240 UNCHANGED

Last Price Updated: 1:45 PM EDT, Sep 18, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Shanghai Junshi Biosciences CO Ltd

Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion

November 04, 2023

Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have...

Via Talk Markets

Week In Review: Apollomics Merges With SPAC To Support Candidates Targeting Difficult-To-Treat Cancers

April 01, 2023

Apollomics, Inc., a US-China biopharma, merged with a SPAC to list on the Nasdaq exchange. At the merger price of $10/share, Apollomics had a market cap of about $900 million, but the shares have...

Via Talk Markets

Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion

February 18, 2023

Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of...

Via Talk Markets

Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug

January 28, 2023

Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...

Via Talk Markets

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.